おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
AcelRx Pharmaceuticals
About
AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of pain and other conditions.
- 51 - 100
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 51 - 100
- Operating Status
- Active
AcelRx Pharmaceuticals is a specialty pharmaceutical company, that engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute postoperative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers.AcelRx Pharmaceuticals was founded in 2005 and is based in Redwood City, California.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 19, 2013 | Post-IPO Debt | $40M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
— | Post-IPO Debt |
